Compare ClearPoint Neuro Inc (CLPT) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Tripadvisor Inc Common Stock — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Tripadvisor Inc Common Stock trades at $14.42 (market cap $1.63B). The key difference: Tripadvisor Inc Common Stock is far larger — about 3.4× ClearPoint Neuro Inc's market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | TRIP | |
|---|---|---|
Market Cap | $478.63M | $1.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $19.14 |
52-Week Low | $8.66 | $9.24 |
Enterprise Value | $506.63M | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Tripadvisor (TRIP) trades at $14.40, up 3.0% today, with technical indicators showing bullish momentum. The company reported mixed Q2 2026 earnings, missing expectations in two of the last three quarters. Recent news highlights the $700 million sale of TheFork to American Express, which may provide capital flexibility. Revenue grew to $1.89 billion in 2025, though net margins remain thin at 0.99%. Analyst consensus is mixed with 60.7% hold ratings and a $13.87 price target slightly below current levels.
The outlook is cautious due to competitive pressures and inconsistent earnings, but the stock shows technical strength. Opportunities include potential benefits from the TheFork sale and travel sector recovery. Key risks are macroeconomic headwinds and execution challenges in core segments. Investors should weigh solid cash flow against high P/E valuation and analyst skepticism for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
